US Stock Movement: SL Science surges on September 28 driven by γδT cell and glioma data

SL Science September 28 Significant Surge Interpretation

Keywords: γδT cells, glioma data

1. On September 24, the company announced preclinical data on γδT cell therapy for glioblastoma: It demonstrated a preferential cytotoxic effect against MGMT-positive, chemotherapy-resistant tumor cells, showed dose-dependent reduction of tumor cells in U87MG, T98G, and LN229 cell lines, and resulted in tumor shrinkage and prolonged survival in intracranial models.

2. From September 24 to 26, the related research was presented in poster form as P-2017 at the 85th Annual Meeting of the Japanese Cancer Association; the study was conducted in collaboration among the company, Taipei Medical University, JY BioMed, and HeXun Biosciences. In vitro comparisons showed that γδT cell cytotoxic activity exceeded that of conventional αβT cells.

(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)